Thai researchers evaluated oligofructans produced from raw sugar using Bacillus subtilis TISTR 001. Rats showed no treatment-related mortality or toxicity at doses up to 2,000 mg/kg/day for 90 days, alongside reported shifts in gut microbial taxa. These are preclinical animal findings and do not establish human safety or benefit.
Key findings
- No mortality or acute toxicity was observed, and LD50 exceeded 2,000 mg/kg. Across 90 days, no treatment-related adverse hematological, biochemical, or histopathological effects were reported, yielding a study-condition NOAEL of 2,000 mg/kg/day. Potentially beneficial commensals increased while some inflammation- or metabolic-dysfunction-associated taxa decreased.
Why this matters globally
The data may support preclinical safety planning for a fermentation-derived food ingredient, but dose translation, manufacturing reproducibility, product characterization, and effects on human microbiota require separate study.
Thai researcher contribution
Chiang Mai University and Kasetsart University teams integrated production, toxicology, pathology, and gut microbiology, extending a Thai microbial strain and raw-sugar substrate toward ingredient development.
Limitations to consider
Rat findings cannot be directly converted into a safe human intake. The NOAEL applies only to this product and test conditions; 90 days does not address chronic, reproductive, or vulnerable-population risks, and microbiome shifts do not demonstrate clinical benefit.
Verify the original sources
NutrientsRead the original article↗DOI: 10.3390/nu18132191